Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 1/2021

23.10.2020 | Case Report

Two case reports of brain metastases in patients with pancreatobiliary neuroendocrine carcinoma

verfasst von: Takaaki Furukawa, Takashi Sasaki, Tsuyoshi Takeda, Takafumi Mie, Ryo Kanata, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Brain metastases are extremely rare in patients with pancreatobiliary neuroendocrine caricnoma (PB-NEC). In this case report, we report two rare cases of brain metastases in patients with PB-NEC. Each patient was diagnosed with brain metastases five and ten months after the initial diagnosis of PB-NEC. It is noteworthy that the serum tumor marker neuron-specific enolase (NSE) or pro-gastrin-releasing peptide (Pro-GRP) was elevated, although the primary and metastatic lesions other than in the brain were under control with systemic chemotherapy. Moreover, the patients complained of no neurological symptoms until they were diagnosed with brain metastases. Although the incidence of brain metastases of PB-NEC is exceedingly low, it is important to keep in mind the possibility of brain metastases during the course of treatment for PB-NEC. In addition, we discuss a strategy of treatment and screening for brain metastases of PB-NEC in this case report.
Literatur
1.
Zurück zum Zitat Sasaki T, Takamatsu M, Furukawa T, et al. Clinicopathological analysis of biliary neuroendocrine neoplasms and chemotherapy for biliary neuroendocrine carcinoma. Tando. 2020;34:153–62. Sasaki T, Takamatsu M, Furukawa T, et al. Clinicopathological analysis of biliary neuroendocrine neoplasms and chemotherapy for biliary neuroendocrine carcinoma. Tando. 2020;34:153–62.
2.
Zurück zum Zitat Korse CM, Taal BG, van Velthuysen ML, et al. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer. 2013;49:1975–83.CrossRef Korse CM, Taal BG, van Velthuysen ML, et al. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer. 2013;49:1975–83.CrossRef
3.
Zurück zum Zitat Kang H, O’Connell JB, Leonardi MJ, et al. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis. 2007;22:183–9.CrossRef Kang H, O’Connell JB, Leonardi MJ, et al. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis. 2007;22:183–9.CrossRef
4.
Zurück zum Zitat Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, et al. Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010. Neuroendocrinology. 2017;104:1–10.CrossRef Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, et al. Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010. Neuroendocrinology. 2017;104:1–10.CrossRef
5.
Zurück zum Zitat Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: A nationwide survey analysis. J Gastroenterol. 2015;50:58–64.CrossRef Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: A nationwide survey analysis. J Gastroenterol. 2015;50:58–64.CrossRef
6.
Zurück zum Zitat Fujii M, Saito H, Shiode J. Rare case of a gallbladder neuroendocrine carcinoma. Clin J Gastroenterol. 2019;12:38–45.CrossRef Fujii M, Saito H, Shiode J. Rare case of a gallbladder neuroendocrine carcinoma. Clin J Gastroenterol. 2019;12:38–45.CrossRef
7.
Zurück zum Zitat Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg. 2005;29:92–101.CrossRef Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg. 2005;29:92–101.CrossRef
8.
Zurück zum Zitat Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRef Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRef
9.
Zurück zum Zitat Chen C, Wang L, Liu X, et al. Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma. Int J Clin Exp Pathol. 2015;8:8218–26.PubMedPubMedCentral Chen C, Wang L, Liu X, et al. Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma. Int J Clin Exp Pathol. 2015;8:8218–26.PubMedPubMedCentral
10.
Zurück zum Zitat Garcia Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103:186–94.CrossRef Garcia Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103:186–94.CrossRef
11.
Zurück zum Zitat Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: Guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19:162–74.CrossRef Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: Guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19:162–74.CrossRef
12.
Zurück zum Zitat Kotecha R, Zimmerman A, Murphy ES, et al. Management of brain metastasis in patients with pulmonary neuroendocrine carcinomas. Technol Cancer Res Treat. 2016;15:566–72.CrossRef Kotecha R, Zimmerman A, Murphy ES, et al. Management of brain metastasis in patients with pulmonary neuroendocrine carcinomas. Technol Cancer Res Treat. 2016;15:566–72.CrossRef
13.
Zurück zum Zitat Prayongrat A, Tao R, Allen PK, et al. Outcomes of stereotactic radiosurgery of brain metastases from neuroendocrine tumors. Neurooncol Pract. 2018;5:37–45.PubMed Prayongrat A, Tao R, Allen PK, et al. Outcomes of stereotactic radiosurgery of brain metastases from neuroendocrine tumors. Neurooncol Pract. 2018;5:37–45.PubMed
14.
Zurück zum Zitat Reveiz L, Rueda JR, Cardona AF. Chemotherapy for brain metastases from small cell lung cancer. Cochrane Database Syst Rev. 2012;6:CD007464. Reveiz L, Rueda JR, Cardona AF. Chemotherapy for brain metastases from small cell lung cancer. Cochrane Database Syst Rev. 2012;6:CD007464.
15.
Zurück zum Zitat Franchino F, Rudà R, Soffietti R. Mechanisms and therapy for cancer metastasis to the brain. Front Oncol. 2018;8:161.CrossRef Franchino F, Rudà R, Soffietti R. Mechanisms and therapy for cancer metastasis to the brain. Front Oncol. 2018;8:161.CrossRef
16.
Zurück zum Zitat Kamath SD, Kumthekar PU. Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease. Front Oncol. 2018;8:414.CrossRef Kamath SD, Kumthekar PU. Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease. Front Oncol. 2018;8:414.CrossRef
17.
Zurück zum Zitat Yu LY, Tang J, Zhang CM, et al. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health. 2017;14:68.CrossRef Yu LY, Tang J, Zhang CM, et al. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health. 2017;14:68.CrossRef
18.
Zurück zum Zitat Farber SH, Tsvankin V, Narloch JL, et al. Embracing rejection: immunologic trends in brain metastasis. Oncoimmunology. 2016;5:e1172153.CrossRef Farber SH, Tsvankin V, Narloch JL, et al. Embracing rejection: immunologic trends in brain metastasis. Oncoimmunology. 2016;5:e1172153.CrossRef
19.
Zurück zum Zitat Johanns T, Waqar SN, Morgensztern D. Immune checkpoint inhibition in patients with brain metastases. Ann Transl Med. 2016;4(Suppl 1):S9.CrossRef Johanns T, Waqar SN, Morgensztern D. Immune checkpoint inhibition in patients with brain metastases. Ann Transl Med. 2016;4(Suppl 1):S9.CrossRef
20.
Zurück zum Zitat Leal T, Chang JE, Mehta M, et al. Leptomeningeal metastasis: challenges in diagnosis and treatment. Curr Cancer Ther Rev. 2011;7:319–27.CrossRef Leal T, Chang JE, Mehta M, et al. Leptomeningeal metastasis: challenges in diagnosis and treatment. Curr Cancer Ther Rev. 2011;7:319–27.CrossRef
21.
Zurück zum Zitat Venur VA, Ahluwalia MS. Novel therapeutic agents in the management of brain metastases. Curr Opin Oncol. 2017;29:395–9.CrossRef Venur VA, Ahluwalia MS. Novel therapeutic agents in the management of brain metastases. Curr Opin Oncol. 2017;29:395–9.CrossRef
22.
Zurück zum Zitat Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol. 2014;16:276.CrossRef Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol. 2014;16:276.CrossRef
23.
Zurück zum Zitat Lin J, Jandial R, Nesbit A, et al. Current and emerging treatments for brain metastases. Oncology (Williston Park). 2015;29:250–7. Lin J, Jandial R, Nesbit A, et al. Current and emerging treatments for brain metastases. Oncology (Williston Park). 2015;29:250–7.
24.
Zurück zum Zitat Soffietti R, Trevisan E, Rudà R. Targeted therapy in brain metastasis. Curr Opin Oncol. 2012;24:679–86.CrossRef Soffietti R, Trevisan E, Rudà R. Targeted therapy in brain metastasis. Curr Opin Oncol. 2012;24:679–86.CrossRef
25.
Zurück zum Zitat Esmaeilzadeh M, Majlesara A, Faridar A, et al. Brain metastasis from gastrointestinal cancers: a systematic review. Int J Clin Pract. 2014;68:890–9.CrossRef Esmaeilzadeh M, Majlesara A, Faridar A, et al. Brain metastasis from gastrointestinal cancers: a systematic review. Int J Clin Pract. 2014;68:890–9.CrossRef
27.
Zurück zum Zitat Krug S, Teupe F, Michl P, et al. Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome. BMC Cancer. 2019;19:362.CrossRef Krug S, Teupe F, Michl P, et al. Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome. BMC Cancer. 2019;19:362.CrossRef
Metadaten
Titel
Two case reports of brain metastases in patients with pancreatobiliary neuroendocrine carcinoma
verfasst von
Takaaki Furukawa
Takashi Sasaki
Tsuyoshi Takeda
Takafumi Mie
Ryo Kanata
Akiyoshi Kasuga
Masato Matsuyama
Masato Ozaka
Naoki Sasahira
Publikationsdatum
23.10.2020
Verlag
Springer Singapore
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 1/2021
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-020-01270-w

Weitere Artikel der Ausgabe 1/2021

Clinical Journal of Gastroenterology 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.